HepCBC Mission Statement

HepCBC is a non-profit organization run by and for people infected and affected by viral hepatitis. Our mission is to provide education, prevention and support to those living with viral hepatitis.

The Week in Review: Nov 2 – Nov 9, 2018

Hot Off The Press!

HepCBC Reaches Inmates through Info-Fairs at 8 Federal Prisons in BC

HepCBC Reaches Inmates through Info-Fairs at 8 Federal Prisons in BC: November 5 - 9, 2018 – Abbotsford, Harrison Mills, Agassiz/Harrison Hot Springs, Mission, and Metchosin, BC One of the most likely places to acquire and/or to be living with hepatitis C is prison, with 20-40X the national prevalence of HCV (https://ctac.ca/wp-content/uploads/2018/01/Access-to-Treatment-in-Federal-Institutions-Web-1.pdf ). Conversely, with its concentrated and highly-reg

The Week in Review: Nov 2 – Nov 9, 2018

Friday, Nov 9, 2018 News Recap: Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018 Gilead Sciences announced results from studies investigating Epclusa in chronic HCV patients with severe renal impairment undergoing dialysis and Harvoni in pediatric HCV patients aged three to five years. As well there was data from Gilead’s HBV cure development program. High Prevalence of Cirrhosis in Adults with Chronic...

Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018

SAN FRANCISCO--(BUSINESS WIRE)--Nov 9, 2018--Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from studies investigating Epclusa ® (sofosbuvir 400mg/velpatasvir 100mg) in chronic hepatitis C virus (HCV) infected patients with severe renal impairment undergoing dialysis and Harvoni ® (ledipasvir/sofosbuvir) in pediatric HCV patients aged three to five years, adding to the efficacy and safety profile of sofosbuvir-based regimens across diverse pa

High Prevalence of Cirrhosis in Adults With Chronic HBV at a Safety-Net Hospital

Of adults with chronic hepatitis B virus (HBV) infection seen at a safety-net hospital, nearly 30% had cirrhosis at initial presentation, with older male patients being at the highest risk, according to a retrospective study published in the Journal of Clinical and Experimental Hepatology. Cirrhosis is a serious consequence of HBV infection that is associated with a financial burden of $13 billion in the United States. Delays in HBV and cirrhosis diagnosi